S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C
sCSD and sB suppress IL-22-induced STAT3 activation in CAV-1 silenced keratinocytes Because STAT3 is involved in keratinocyte proliferation and affects the expression of several cytokines 13 and CAV-1 downregulation induces STAT3 activation in keratinocytes 6 , we examined whether STAT3 activation is targeted by versions of CSD
DAILY USE SUPPORT - Designed for consistent use over time
Week 1: Dose: 50mcg Frequency: Once, on a night when you can sleep in the next morning Timing: 2-3 hours before intended sleep Purpose: Assess basic tolerance and response Week 2: Dose: 75-100mcg Frequency: 2-3 times during the week Timing: 1-2 hours before bed Purpose: Establish baseline effective dose During this assessment phase, track sleep quality subjectively and, if possible, with a wearable device that measures sleep stages